Open Tender Watch
Menu v
ACCESS EN PT
← Companies Company PT

LILLY-PORTUGAL PRODUTOS FARMACÊUTICOS LDA

NIF 500165602
↓ CSV ↓ JSON
Risk Flags
A1 · Repeat Direct Award €5,973,771 39 contracts
Same supplier receives ≥2 direct awards in 36 months with cumulative value above the CCP Art. 113 §2 statutory cap
HIGH €5,973,771 39 contracts
A2 · Late Publication €163,120,899,724 1,974 contracts
Contract published to BASE more than 10 days after the signing date
LOW €163,120,899,724 1,974 contracts
A5 · Threshold Splitting €9,174,335 74 contracts
Contract value falls within 5% below a procedural threshold (€5K / €20K / €75K / €150K / €5.35M). Score: 35 · Severity: Medium.
HIGH €9,174,335 74 contracts
A6 · Low Competition €2,517,511 29 contracts
Only one bidder participated in a competitive procedure
MEDIUM €2,517,511 29 contracts
A9 · Price Overrun €87,496 3 contracts
Effective price exceeds base price by >50% (score 30) or >100% (score 55); or effective price is <50% of base (score 10, possible predatory bid or data error). Severity: Medium/High/Low.
HIGH €48,172 1 contracts
MEDIUM €39,324 2 contracts
A9 · Abnormal Price Reduction €166,650,922,544 973 contracts
Effective price exceeds base price by >50% (score 30) or >100% (score 55); or effective price is <50% of base (score 10, possible predatory bid or data error). Severity: Medium/High/Low.
LOW €166,650,922,544 973 contracts
B5 · Benford's Law Deviation €147,456,136,800 1 contracts
Entity's contract values deviate from the Benford leading-digit distribution (chi-square goodness-of-fit, min 20 contracts). Score: 35 (p<0.05) or 55 (p<0.01).
MEDIUM €147,456,136,800 1 contracts
C3 · Missing Mandatory Fields €2,344,688 41 contracts
CPV code, procedure type, or base price absent for the procedure type, or base price exceeds ±€1 trillion (implausible data entry). Score: 20 · Severity: Low.
LOW €2,344,688 41 contracts

Procurement Network

Aggregated links between this entity and connected counterparties

Public view excludes person-level links and tax identifiers.

Loading network…
Legend Focus entity Public body Company Anonymized individual

Contracts by Contracting Authority

48
€148,111,495,210
320
€3,143,255,591
37
€640,580,803
174
€616,647,934
131
€610,415,497
49
€598,113,865
21
€596,211,790
90
€596,055,636
118
€576,152,448
28
€568,112,332
48
€557,656,688
274
€555,949,159
9
€555,906,932
29
€545,268,445
19
€538,158,250
8
€535,170,486
39
€520,053,551
14
€511,618,075
16
€507,406,114
27
€494,885,385
Page 1 of 4 · 62 authorities
Next →

All Contracts Won

Signal: All A1 · Repeat Direct Award A2 · Late Publication A5 · Threshold Splitting A6 · Low Competition A9 · Price Overrun A9 · Abnormal Price Reduction B5 · Benford's Law Deviation C3 · Missing Mandatory Fields

Page 1 of 2 · 74 contracts

31/1284/2026 - Medicamento Abemaciclib 50 mg Comp
PT · 13688928 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A2 · Late Publication
€19,543 2026-02-13
Medicamentos
PT · 12065625 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication +1
€19,119 2025-11-06
Medicamentos
PT · 12127061 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication +1
€19,119 2025-11-06
Q1/2318/2025 - AGREGAÇÃO URGENTE - MEDICAMENTOS DO FORO ONCOLÓGICO E IMUNOMODULADORES
PT · 11977105 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A2 · Late Publication +1
€5,294,078 2025-10-22
ADCM 4062/25 - MEDICAMENTOS DIVERSOS
PT · 11791803 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication
€71,330 2025-09-29
ADCM3064/25 - MEDICAMENTOS DIVERSOS
PT · 11616256 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication +1
€149,723 2025-07-11
161007325-Aquisição Medicamento Aue 202502305 LILLY
PT · 12504852 · Contratação excluída II
A5 · Threshold Splitting A2 · Late Publication
€74,347 2025-07-07
ADCM 2693/25 - MEDICAMENTOS DIVERSOS
PT · 11594033 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication +1
€147,567 2025-06-09
Aquisição de Selpercatinib, ao abrigo do acordo quadro 2024/1077
PT · 11654122 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A2 · Late Publication
€19,516 2025-05-16
ABEMACICLIB 150MG COMP (PC.01992.2025)
PT · 11631432 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication
€19,543 2025-04-23
Aquisição de Selpercatinib 40 mg Cáps - novas quantidades AQ 2024/1077– Ano 2025
PT · 11366931 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting
€19,516 2025-04-22
Aquisição de Medicamentos do foro oncológico e imunomoduladores, ao abrigo do acordo quadro 2023/491, para o ano 2025
PT · 11749095 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A2 · Late Publication
€144,806 2025-04-10
Aquisição de Anacinra 100 mg/0.67 ml sol inj ser 0.67 ml SC, Bussulfano 60 mg/10 ml sol inj fr 10 ml IV, Fluorouracilo 50 mg/ml sol inj fr 100 ml IA IV, Interferão Beta-1A (Avonex seringas) 6 M.U.I. pó sol inj fr IM, Lenvatinib 10 mg cáps (Lenvima), Leuprorrelina 45 mg pó sol inj ser SC, Ramucirumab 10 mg/ml sol inj fr 50 ml IV e Vinorrelbina 20 mg cáps
PT · 11371892 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A2 · Late Publication +1
€71,770 2025-04-01
ABEMAciclib 100mg comp. revestido
PT · 11313242 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication
€19,543 2025-01-13
ABEMAciclib
PT · 11287473 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication
€19,543 2025-01-08
MEDICAMENTOS
PT · 11130066 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication +1
€74,145 2024-12-18
ABEMAciclib
PT · 11198942 · Ajuste Direto Regime G...
A5 · Threshold Splitting C3 · Missing Mandatory Fields
€19,543 2024-12-16
050104292024 C/ BASE NO CPA 2023_491
PT · 11093397 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting
€19,543 2024-12-13
MEDICAMENTOS
PT · 11140349 · Ajuste Direto Regime G...
A5 · Threshold Splitting C3 · Missing Mandatory Fields
€147,407 2024-12-10
31/205/2025 - Medicamento " Abemaciclib "
PT · 11254302 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting C3 · Missing Mandatory Fields
€73,287 2024-11-21
ABEMAciclib 100mg comp. revestido
PT · 11112117 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication
€19,543 2024-11-05
VÁRIOS MEDICAMENTOS
PT · 10962746 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting
€74,243 2024-10-08
AQUISIÇÃO DE ABEMACICLIB 100 MG COMP E SECUCINUMAB 300 MG/2 ML SOL INJ CANETA 2 ML SC
PT · 10953606 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A9 · Abnormal Price Reduction
€74,748 2024-09-30
Convite à apresentação de propostas ao abrigo do(s) acordo(s)-quadro 2022/40 - Medicamentos antirretrovíricos para o tratamento da infeção por VIH; 2023/304 - Medicamentos do grupo 4: sangue; 2023/305 - Medicamentos do aparelho cardiovascular; 2023/481 - Medicamentos diversos; 2023/491 - Medicamentos do foro oncológico e imunomoduladores; 2023/492 - Medicamentos anti-infeciosos e 2024/780 - Medicamentos do aparelho locomotor, usados no tratamento das doenças endócrinas e hormonas para aquisição de medicamentos
PT · 11228682 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting C3 · Missing Mandatory Fields
€19,167 2024-09-26
BARICITINB 4MG COMP (PC.02876.2024)
PT · 10933883 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A2 · Late Publication
€72,767 2024-09-04
Abemaciclib 100mg comp. revestido
PT · 10978684 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication
€19,543 2024-08-29
Abemaciclib 100mg
PT · 10919499 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication
€19,543 2024-08-29
AQUISICAO DE VARIOS MEDICAMENTOS AO ABRIGO DOS AQ DA SPMS 18- 2024- ULSLO
PT · 12822968 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting C3 · Missing Mandatory Fields
€147,941 2024-08-29
Abemaciclib
PT · 10941992 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication
€19,543 2024-08-14
1544224 Abemaciclib 150 mg Comp CPA 2023/491 – Novas qt
PT · 10983926 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A2 · Late Publication
€72,160 2024-07-01
IMUNOMODULADORES - IXECIZUMAB
PT · 10405738 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting
€19,924 2023-12-22
050103692023 - C/ BASE NO CPA 2021_06
PT · 10409205 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A2 · Late Publication
€19,924 2023-12-04
MEDICAMENTOS
PT · 10188878 · Ajuste Direto Regime G...
A5 · Threshold Splitting A9 · Abnormal Price Reduction
€19,146 2023-08-09
Vários Medicamentos
PT · 9626916 · Ajuste Direto Regime G...
A5 · Threshold Splitting A1 · Repeat Direct Award +1
€72,294 2022-12-05
GALCANEZUMAB 120 MG/1 ML SOL INJ CANETA 1 ML SC
PT · 9610934 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication
€19,178 2022-11-14
GALCANEZUMAB 120 MG/1 ML SOL INJ CANETA 1 ML SC
PT · 9584429 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication
€19,178 2022-09-28
MEDICAMENTOS
PT · 9310425 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication +1
€19,606 2022-03-23
MEDICAMENTOS
PT · 9309338 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication +1
€19,550 2022-02-16
GALCANEZUMAB 120MG/1ML SOL INJ 1 ML SC
PT · 9101332 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication
€19,178 2022-02-04
Aquisição do medicamento SELPERCATINIB 80 MG CÁPS
PT · 8803570 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication
€71,806 2022-01-13
GALCANEZUMAB 120 MG/1 ML SOL INJ SER 1 ML SC
PT · 9594948 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication
€19,178 2022-01-03
MEDICAMENTOS
PT · 8469541 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication +1
€72,869 2021-11-24
AQUISIÇÃO DE MEDICAMENTOS DO APARELHO LOCOMOTOR, USADOS NAS DOENÇAS ENDÓCRINAS E HORMONAS, AO ABRIGO DO ACORDO QUADRO 2021/047 DOS SPMS, EPE
PT · 9324985 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A2 · Late Publication +1
€74,554 2021-11-16
MEDICAMENTOS
PT · 8466549 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication +1
€74,010 2021-11-03
Pemetrexedo 500 mg Pó conc sol inj Fr IV CPA 2021/06 (2)
PT · 7804252 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A2 · Late Publication
€19,500 2021-07-30
Vários Medicamentos
PT · 7786785 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A2 · Late Publication
€71,491 2021-07-08
2021006523 – Pernetrexedo 500mg Pó conc sol inj Fr IV
PT · 7776323 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication
€4,870 2021-06-22
2021003948 - Pemetrexedo 500 mg Pó conc sol inj Fr IV
PT · 7886917 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A2 · Late Publication
€4,870 2021-04-01
Q1/1350/2021 Ixecizumab
PT · 7581685 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting
€4,981 2021-03-23
Aprov/PRT 21000527 - AP 136
PT · 7490436 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A9 · Abnormal Price Reduction
€19,856 2021-02-18
Next →
Overview
Total Value Won
€166,749,658,566
Contracts Won
2,781
Score 94800 · CRITICAL RISK
NIF
500165602
Country
PT
Directors & Officers

Personal data is pseudonymised for public access. Authenticate with a journalist token to view full names and NIFs.

  • A.D. [P-4240]
    Gerente
    since 2024-02-12
  • J.E. [P-675a]
    Gerente
    since 2012-12-28
  • J.E. [P-675a]
    Gerente
    since 2018-02-05
  • J.C. [P-aa14]
    Gerente
    since 2026-01-30
  • D.P. [P-a798]
    Sócio
    since 2008-06-25
  • E.L. [P-4640]
    Sócio
    since 2008-06-25
  • A.L. [P-40e8]
    Gerente
    2016-12-02 → 2024-02-12
  • C.B. [P-3a7c]
    Gerente
    2024-11-22 → 2026-01-30
  • E.G. [P-a9c9]
    Gerente
    2008-11-05 → 2012-03-20
  • L.E. [P-5eeb]
    Gerente
    2024-04-19 → 2024-11-22
  • N.D. [P-c99e]
    Gerente
    2018-02-05 → 2024-04-19
  • P.L. [P-166e]
    Gerente
    2012-03-20 → 2012-12-28
  • V.R. [P-7bf5]
    Gerente
    until 2016-12-02
Ownership & Registries

Beneficial ownership data (shareholders, directors, ultimate beneficial owners) is not yet imported. Links below open external public registries.

Registo Comercial (MJ) ↗ RCBE — Beneficial Ownership Register ↗

Full RCBE access requires judicial authentication (CJEU 2022 ruling limits public exposure).

Search in TED (EU procurement) ↗
Phase 7 — ownership layer planned